News and Trends 22 Sep 2022 Research identifies new treatment target for CNS injury and neurological disease Researchers in Birmingham in the U.K. have identified a potential target for drugs to treat long-term neurological conditions like Alzheimer’s Disease and foster nerve regeneration in central nervous system injuries. The research, published last week in Science Advances, is part of a workstream exploring the signaling pathways that respond to DNA damage, which is seen […] September 22, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2022 Hoag’s high hopes for new drug with Alzheimer’s disease trial Hoag’s Pickup Family Neurosciences Institute is initiating a clinical trial for what it says is a promising new investigational treatment for Alzheimer’s disease (AD). The phase I study will determine the safety and tolerability of a single intravenous (IV) dose and multiple IV doses of ACU193. Hoag is seeking individuals who have memory problems to […] September 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Sep 2022 Liquid-interface assisted SERS could lead to earlier detection of Alzheimer’s In a new publication in Opto-Electronic Advances, Japanese researchers discussed label-free trace detection of bio-molecules by liquid-interface assisted surface-enhanced Raman scattering (SERS) using a microfluidic chip. SERS has attracted attention in biotechnology. This is due to its high sensitivity to localized surface plasmon resonance of nanostructured metals. Trace detection of bio-molecules with large molecular weight […] September 12, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Sep 2022 Alzinova announces new positive safety review for Alzheimer’s study Alzinova AB says a second external safety review has been carried out of its clinical phase 1b study. This resulted in a positive assessment to continue the study as planned. Behind the review is an independent expert group, Data and Safety Monitoring Board (DSMB), which continuously reviews the study. Based on the patients included in […] September 7, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2022 Proxidrugs: a new tool to fight pathogens? Scientists at the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP in Germany are working with partners to develop a new drug class. Proxidrugs (or proximity-inducing drugs) utilize cells’ waste disposal system as potential new treatments for cancer, infections and Alzheimer’s disease. Aimo Kannt, head of drug discovery and preclinical research at Fraunhofer ITMP in […] September 1, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jun 2022 Biogen, citing insurance challenges, shutters one of its Aduhelm studies A company says it was forced to end an observational trial of Alzheimer’s drug, Aduhelm, after a ruling by US federal insurance program, Medicare. Biogen said a recent coverage decision by Medicare has forced it to abandon the trial of the drug after enrolling just 29 participants. The company said it made the decision to […] June 28, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2022 Boost for dementia gene-based therapies The Cell and Gene Therapy Catapult (CGT Catapult) and the UK Dementia Research Institute (UK DRI) have announced a collaboration to accelerate the clinical development of adeno-associated virus (AAV) based gene therapies for dementia. Since 2015, dementia has been one of the leading causes of mortality in the UK. While new and improved treatments for […] June 20, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Sponsored by WuXi AppTec 22 Sep 2021 Discovering New Therapeutic Targets for Alzheimer’s Disease Effective therapies for neurodegenerative diseases like Alzheimer’s are urgently needed. But developing new drugs is difficult, time-consuming, and expensive, with a high risk of failure. Strategic partnerships can help biotech companies manage costs and access the latest technologies to drive innovation and advance novel therapy ideas. A serious unmet medical need Finding treatments for neurodegenerative […] September 22, 2021 - 7 minutesmins - By Julia Kaiser Share WhatsApp Twitter Linkedin Email
News and Trends 2 Sep 2021 AC Immune’s Mixed Phase II Results Buoy Alzheimer’s Research An Alzheimer’s disease drug developed by AC Immune and Genentech has drawn conflicting phase II results this week, raising tentative hopes for the field of treatments targeting the protein tau. For decades, the major culprit responsible for Alzheimer’s disease was suggested to be the buildup of a protein called amyloid-beta in the brain. Blocking this […] September 2, 2021 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2021 Danish Dementia Startup Launches Amid Maturing Nordic Biotech Scene Muna Therapeutics debuted with the Danish biotech sector’s biggest-ever Series A round earlier this month. This showcases the rapid growth taking place in the biotech industry in the Nordic region. Muna Therapeutics’ €62M ($73M) investment was co-led by the Danish investor Novo Holdings through its early-stage arm Novo Seeds. The startup was first set up […] July 20, 2021 - 4 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
Best in Biotech 30 Jun 2021 Scotland’s Top 10 Biotech Companies to Watch Out For Scotland has a thriving life sciences ecosystem with strengths in oncology, genetic engineering, and industrial biotech. Let’s pick up the bagpipes as we tour the top 10 biotech companies in Scotland. Scotland is the UK’s second-most populous country, boasting picturesque scenery, a rich history, and a strong focus on sustainability. There is a diverse range […] June 30, 2021 - 11 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jun 2021 FDA Approval of Biogen’s Drug Boosts European Alzheimer’s Space The FDA shocked many life sciences observers by greenlighting Biogen’s treatment candidate for Alzheimer’s last week. Yet, for much of the Alzheimer’s disease community on both sides of the Atlantic, the decision also brings cautious hope. Controversy recently erupted when the FDA conditionally granted accelerated approval to Biogen’s aducanumab, making it the first approved treatment […] June 17, 2021 - 6 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email